BORDEAUX, France--(BUSINESS WIRE)--Dec 16, 2025--
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/
Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver programs, further strengthen our regenerative medicine platform and pursue strategic partnerships such as the one in place with Vertex for their Type 1 Diabetes pipeline. I would like to thank Frédéric for his leadership over the past 5 years which have been transformational for TreeFrog, moving from an early-stage research platform to a development engine with operations in France and in the US.”
Mark Rothera has built a strong reputation, driving the successful scale up of multiple biotech companies, including most recently, Viracta, Silence Therapeutics and Orchard Therapeutics. Renowned for building strong leadership teams that advance novel medicines through development to regulatory approval and commercialization, Mark has focused much of his career on specialty diseases and novel modalities including gene therapy and RNAi therapies. In his earlier career, he held commercial lead roles in PTC Therapeutics, Aegerion, Shire, and GSK. Mark serves on the Board of GenPharm and holds an M.A. in Natural Sciences from Cambridge University and an M.B.A. from the European Institute for Business Administration (INSEAD).
“I am excited to join TreeFrog at this pivotal moment,” said Rothera . “I am proud to take the lead on delivering the vision of the co-founders - ‘Cell Therapy for All’. The company has developed technology that can unlock the potential of regenerative medicine to transform outcomes across a range of serious conditions. I am looking forward to working with the talented team at TreeFrog and our partners to advance breakthrough medicines to millions of patients.”
Ends
About TreeFrog Therapeutics
TreeFrog Therapeutics is a French-based regenerative medicine biotech set to unlock access to cell therapies for millions of patients. TreeFrog is unique in its approach to cell therapy development, bringing together biophysicists, cell biologists and bioproduction engineers to address the challenges of the industry – producing and differentiating cells of quality at unprecedented scale, cost-effectively. To succeed in their mission of Cell Therapy for all, TreeFrog operates a business model that includes its own therapeutic programs and partnerships with leading biotech and industry players. Since 2021, the company has raised $82 million to advance a pipeline of stem cell-based therapies in regenerative medicine.
For further information, visit www.treefrog.fr
Mark Rothera, CEO TreeFrog Therapeutics
NEW YORK (AP) — The U.S. stock market drifted through a mixed day of trading Tuesday after reports on the economy did little to clear uncertainty about where interest rates may be heading.
The S&P 500 slipped 0.2% and remains a bit below its all-time high set last week. The Dow Jones Industrial Average dipped 302 points, or 0.6%, and the Nasdaq composite rose 0.2%.
Treasury yields eased in the bond market after one report said the U.S. unemployment rate was at its worst level since 2021, but employers also added more jobs last month than economists expected. A separate report, meanwhile, said an underlying measure of strength for revenue at U.S. retailers grew more in October than economists expected.
The mixed data meant little change in traders’ hopes that the Federal Reserve may continue to cut interest rates further in 2026. What the Fed does with interest rates is a top driver for financial markets because lower rates can boost the economy and prices for investments, even if they also may worsen inflation.
A report coming on Thursday will show how bad inflation was last month, and economists expect it to show prices for U.S. consumers continue to rise faster than anyone would like.
A report released on Tuesday after U.S. stocks began trading suggested price pressures are rising sharply, with average selling prices for businesses climbing at one of the fastest rates since the middle of 2022. The preliminary data from S&P Global also said growth for overall business activity slowed to its weakest level since June.
“Higher prices are again being widely blamed on tariffs, with an initial impact on manufacturing now increasingly spilling over to services to broaden the affordability problem,” according to Chris Williamson, chief business economist at S&P Global Market Intelligence.
On Wall Street, the sharpest losses came from companies in the oil business as prices for crude kept sliding.
Expectations that companies are pumping more than enough oil to meet the world’s demand have sent the price for a barrel of benchmark U.S. crude to its lowest level since 2021. It fell 2.7% Monday, as did Brent crude, the international standard. U.S. crude settled at $55.27 per barrel, while Brent settled at $58.92.
That drove APA’s stock down 5.2%. Marathon Petroleum sank 4.7% and Halliburton dropped 4.3% for some of Wall Street’s larger losses.
Artificial-intelligence technology stocks, meanwhile, were mixed after dominating the market in recent days.
Oracle rose 2%, and Broadcom added 0.4%. They both had dropped to sharp losses last week, even though both reported stronger profits for the latest quarter than analysts expected.
But CoreWeave, which rents out access to top-of-the-line AI chips, fell 3.9%.
Questions remain about whether all the spending underway on AI technology will produce the kind of profits and productivity that will make it worth the expense.
Elsewhere on Wall Street, Pfizer fell 3.4% after giving a forecast for profit in 2026 that was below what some analysts expected. Its forecast for revenue next year was close to analysts’ expectations.
Kraft Heinz added 0.7% after saying Steve Cahillane, who was most recently CEO of Kellanova, will join as CEO on Jan. 1. After Kraft Heinz splits into two companies, which is expected to happen in the second half of 2026, Cahillane will lead the one that will hold onto the Heinz, Philadelphia and Kraft Mac & Cheese brands.
All told, the S&P 500 fell 16.25 points to 6,800.26. The Dow Jones Industrial Average dropped 302.30 to 48,114.26, and the Nasdaq composite rose 54.05 to 23,111.46.
In stock markets abroad, indexes fell across much of Europe and Asia.
Japan’s Nikkei 225 dropped 1.6% ahead of an expected hike to interest rates by the Bank of Japan later this week.
Other markets in Asia also had some of the world’s sharper swings. South Korea’s Kospi dropped 2.2%, while indexes fell 1.5% in Hong Kong and 1.1% in Shanghai.
In the bond market, the yield on the 10-year Treasury fell to 4.14% from 4.18% late Monday.
AP Business Writers Matt Ott and Elaine Kurtenbach contributed.
Specialists Alex Weitzman, left, and Meric Greenbaum work on the floor of the New York Stock Exchange, Thursday, Dec. 11, 2025. (AP Photo/Richard Drew)
A television displays a news conference with Fed chairman Jerome Powell on the floor at the New York Stock Exchange in New York, Wednesday, Dec. 10, 2025. (AP Photo/Seth Wenig)
Traders work on the floor at the New York Stock Exchange in New York, Wednesday, Dec. 10, 2025. (AP Photo/Seth Wenig)
Currency traders pass by a screen showing the Korea Composite Stock Price Index (KOSPI), top center left, and the foreign exchange rate between U.S. dollar and South Korean won, top center, at the foreign exchange dealing room of the Hana Bank headquarters, in Seoul, South Korea, Friday, Dec. 5, 2025. (AP Photo/Ahn Young-joon)
